Member Publications - 1999

January

  1. Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. Wagner JA, Nepomuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, Moss RB, Wine JJ, Gardner P. J Gene Med. 1999 Jan-Feb;1(1):13-21.

February

  1. Allergic bronchopulmonary aspergillosis and cystic fibrosis. Milla CE. Pediatr Pulmonol. 1999 Feb;27(2):71-3.

  2. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Nepomuceno IB, Esrig S, Moss RB. Chest. 1999 Feb;115(2):364-70.

  3. K+-channel blockade inhibits shear stress-induced pulmonary vasodilation in the ovine fetus. Storme L, Rairigh RL, Parker TA, Cornfield DN, Kinsella JP, Abman SH. Am J Physiol. 1999 Feb;276(2 Pt 1):L220-8.

  4. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. Laryngoscope. 1999 Feb;109(2 Pt 1):266-74.

March

April

  1. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss RB, Ramsey B, Redding G, Rubio T, Williams-Warren J, Wilmott R, Wilson HD, Yogev R. J Pediatr. 1999 Apr;134(4):413-21.

  2. Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure. Dobyns EL, Cornfield DN, Anas NG, Fortenberry JD, Tasker RC, Lynch A, Liu P, Eells PL, Griebel J, Baier M, Kinsella JP, Abman SH. J Pediatr. 1999 Apr;134(4):406-12.

May

June

  1. High levels of peroxynitrite are generated in the lungs of irradiated mice given cyclophosphamide and allogeneic T cells. A potential mechanism of injury after marrow transplantation. Haddad IY, Panoskaltsis-Mortari A, Ingbar DH, Yang S, Milla CE, Blazar BR. Am J Respir Cell Mol Biol. 1999 Jun;20(6):1125-35.

  2. NO causes perinatal pulmonary vasodilation through K+-channel activation and intracellular Ca2+ release. Saqueton CB, Miller RB, Porter VA, Milla CE, Cornfield DN. Am J Physiol. 1999 Jun;276(6 Pt 1):L925-32.

  3. Standardized high-resolution CT of the lung using a spirometer-triggered electron beam CT scanner. Robinson TE, Leung AN, Moss RB, Blankenberg FG, al-Dabbagh H, Northway WH. AJR Am J Roentgenol. 1999 Jun;172(6):1636-8.

  4. Two novel mutations in a cystic fibrosis patient of Chinese origin. Wagner JA, Vassilakis A, Yee K, Li M, Hurlock G, Krouse ME, Moss RB, Wine JJ. Hum Genet. 1999 Jun;104(6):511-5.

July

  1. Recombinant human DNase in cystic fibrosis. Milla CE. Lancet. 1999 Jul 31;354(9176):428.

August

  1. Interactions of keratinocyte growth factor with a nitrating species after marrow transplantation in mice. Haddad IY, Panoskaltsis-Mortari A, Ingbar DH, Resnik ER, Yang S, Farrell CL, Lacey DL, Cornfield DN, Blazar BR. Am J Physiol. 1999 Aug;277(2 Pt 1):L391-400.

September

  1. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, Sardesai S, Walsh-Sukys MC, McCaffrey MJ, Cornfield DN, Bhutani VK, Cutter GR, Baier M, Abman SH. Lancet. 1999 Sep 25;354(9184):1061-5.

October

  1. Aerosol delivery of diethylenetriamine/nitric oxide, a nitric oxide adduct, causes selective pulmonary vasodilation in perinatal lambs. Cornfield DN, Martin EB, Hampl V, Archer SL. J Lab Clin Med. 1999 Oct;134(4):419-25.

November

  1. Randomized, controlled trial of low-dose inhaled nitric oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension. Cornfield DN, Maynard RC, deRegnier RA, Guiang SF 3rd, Barbato JE, Milla CE. Pediatrics. 1999 Nov;104(5 Pt 1):1089-94.

December